AbbVie Touts Subgroup Data in Phase II Atrial Fibrillation Miss

Despite missing its primary endpoint in a Phase II trial, AbbVie is holding out hope that its investigational neurotoxin, AGN-151607, can be effective in preventing postoperative atrial fibrillation in some cardiac surgery patients.